# Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

> **NCT01197885** · PHASE2 · COMPLETED · sponsor: **Ganymed Pharmaceuticals GmbH** · enrollment: 54 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** IMAB362

## Key facts

- **NCT ID:** NCT01197885
- **Lead sponsor:** Ganymed Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-03
- **Primary completion:** 2015-08-13
- **Final completion:** 2015-08-13
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197885, "Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01197885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*